John C. McMichael
National Institutes of Health
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John C. McMichael.
Infection and Immunity | 2001
Wei-Gang Hu; Jing Chen; John C. McMichael; Xin-Xing Gu
ABSTRACT A monoclonal antibody (MAb), designated MAb 8E7 (immunoglobulin G3), specific for Moraxella catarrhalislipooligosaccharide (LOS) was evaluated for its functional activity in vitro and in a mouse model of colonization. Enzyme-linked immunosorbent assay (ELISA) demonstrated that the MAb 8E7 could be prepared to a high titer against LOS of the homologous strain 035E, and that it had bactericidal activity. MAb 8E7 reacted with M. catarrhalisserotype A and C LOSs but not serotype B LOS, as measured by ELISA and Western blotting. On the basis of published structures of LOSs, this suggests that the epitope recognized by MAb 8E7 is directed to a common sequence of either α-GlcNAc-(1→2)-β-Glc-(1→ at the branch substituting position 4 of the trisubstituted Glc residue or a terminal tetrasaccharide α-Gal-(1→4)-β-Gal-(1→4)-α-Glc-(1→2)-β-Glc-(1→ at the branch substituting position 6 of the trisubstituted Glc residue. In a whole-cell ELISA, MAb 8E7 reacted with 70% of the 30 wild-type strains and clinical isolates tested. Immuno-electron microscopy demonstrated that MAb 8E7 reacted with a cell surface-exposed epitope of LOS on strain O35E. MAb 8E7 inhibited the adherence of strain O35E to Chang conjunctival epithelial cells by 90%. Passive immunization with MAb 8E7 could significantly enhance the clearance of strain O35E from mouse lungs in an aerosol challenge mouse model. This enhanced bacterial clearance was inhibited when MAb 8E7 was absorbed by M. catarrhalis serotype A LOS, indicating that the M. catarrhalis LOS-directed antibody may play a major role in the enhancement of M. catarrhalis clearance from lungs. These data suggest that MAb 8E7, which recognizes surface-exposed LOS of M. catarrhalis, is a protective antibody against M. catarrhalis.
Infection and Immunity | 2007
Dai-Fang Liu; John C. McMichael; Steven M. Baker
ABSTRACT The outer membrane protein CD of Moraxella catarrhalis is considered to be a potential vaccine antigen against Moraxella infection. We purified the native CD from isolate O35E, administered it to mice, and detected considerable titers of anti-CD antibodies. Anti-CD sera were cross-reactive towards six different M. catarrhalis isolates and promoted bacterial clearance of O35E in a pulmonary challenge model. To circumvent the difficulty of generating large quantities of CD from M. catarrhalis for vaccine use, the CD gene from O35E was cloned into Escherichia coli, and the recombinant CD, expressed without a signal sequence or fusion tags, represented ∼70% of the total E. coli proteins. The recombinant CD formed inclusion bodies that were solubilized with 6 M urea and then purified by ion-exchange chromatography, a procedure that produced soluble CD of high purity and yield. Mice immunized with the purified recombinant CD had significant titers of anti-CD antibodies that were cross-reactive towards 24 different M. catarrhalis isolates. Upon challenge, these mice showed enhanced bacterial clearance of both O35E and a heterologous M. catarrhalis isolate, TTA24. In an in vitro assay, antisera to either the native or the recombinant CD inhibited the binding activity of CD to human tracheobronchial mucin in a serum concentration-dependent manner, and the extent of inhibition appeared to correlate with the corresponding anti-CD antibody titer and whole-cell enzyme-linked immunosorbent assay titer. Our results demonstrate that the recombinant CD is a promising vaccine candidate for preventing Moraxella infection.
Journal of Chromatography B: Biomedical Sciences and Applications | 2001
Michael J. Fiske; Ross A. Fredenburg; Karl R. VanDerMeid; John C. McMichael; Rasappa Arumugham
The UspA2 protein from the bacterium Moraxella catarrhalis is a potential vaccine candidate for preventing human diseases caused by this organism. Before a vaccine can be administered parentally, the level of endotoxin must be reduced as much as possible. However, in this case the endotoxin was very tightly complexed with the UspA2 protein and could not be dissociated with Triton X-100. It was found that it dissociated from the protein with the zwitterionic detergents Zwittergent 3-12 and Zwittergent 3-14. The endotoxin could then be separated from the protein by either ion-exchange or gel filtration chromatography. Using the limulus amoebocyte lysate assay for quantitation, the endotoxin was reduced approximately 20,000-fold. The removal of residual endotoxin from UspA2 preparations had no detrimental effect on the immunological properties of the protein. Mouse antisera raised against UspA2 prior to, and following endotoxin reduction exhibited comparable antibody and bactericidal titers against the tested strains. Further, mice immunized with both preparations, followed by pulmonary challenge with either a homologous or a heterologous isolate, exhibited comparable levels of clearance.
Vaccine | 1999
Dexiang Chen; John C. McMichael; Karl R. VanDerMeid; Amy W. Masi; Eric Bortell; Jeffrey D. Caplan; Deb N. Chakravarti; Vicki Barniak
An outer membrane protein from Moraxella catarrhalis with a mass of 74-kDa was isolated and evaluated as a vaccine candidate. The 74-kDa protein binds transferrin, and appears to be related to the other proteins from the organism that are reported to bind transferrin. The 74-kDa protein possessed conserved epitopes exposed on the bacterial surface. This is based on the reactivity with whole bacterial cells as well as complement dependent bactericidal activity of sera from mice immunized with the isolated proteins from the O35E and TTA24 isolates. However, there was divergence in the degree of antibody cross-reactivity with the protein from one strain to another. This serotypic divergence was reflected in both the complement-dependent bactericidal activities of the antibodies elicited in mice and the capacity of immune mice to clear the bacteria in a murine pulmonary model. Antibodies affinity purified from human plasma lacked bactericidal activity even though they were reactive with all the tested isolates. The 74-kDa protein appears to be a good vaccine candidate, but more studies are needed to understand its antigenic variability and whether antibodies toward it are protective.
International Congress Series | 2003
John C. McMichael; Kathryn Mason; Duzhang Zhu; Bruce A. Green
Abstract Nontypeable Haemophilus influenzae and Moraxella catarrhalis colonize and infect human mucosal membranes. To improve protection against these pathogens, we have explored the capacity of vaccines to elicit an immune response when intranasally delivered. In these studies, we immunized Balb/c mice with mixtures of the H. influenzae (NTHi) P4 and P6 OMPs and the M. catarrhalis UspA2 serum resistance factor. The addition of an adjuvant was needed to achieve an acceptable response. While detoxified cholera toxin adjuvants (CT-CRMs) induced the strongest immune response, other adjuvants such as the MPL homologues also elicited good responses. When mixed with these adjuvants, the antigen mixture elicited high antibody levels in the serum and mucosal fluids of mice, as well as serum complement-dependent bactericidal activity. The intranasally immunized mice also exhibited a capacity to limit colonization by the two bacterial species upon challenge. These results suggest that an efficacious intranasally delivered vaccine can be developed for people. However, to determine if similar responses can be elicited in people, the intranasal delivery of these antigens and adjuvants needs to be subjected to a clinical trial.
Infection and Immunity | 1998
John C. McMichael; Michael J. Fiske; Ross A. Fredenburg; Deb N. Chakravarti; Karl R. VanDerMeid; Vicki Barniak; Jeffrey D. Caplan; Eric Bortell; Steven M. Baker; Rasappa Arumugham; Dexiang Chen
Infection and Immunity | 1999
Dexiang Chen; Vicki Barniak; Karl R. VanDerMeid; John C. McMichael
Vaccine | 2004
Kathryn Mason; Duzhang Zhu; Catherine A. Scheuer; John C. McMichael; Gary W. Zlotnick; Bruce A. Green
Fems Immunology and Medical Microbiology | 2006
Dai-Fang Liu; Xiaoling Xie; Maria Mastri; Maria Fortuna-Nevin; Christopher Colocillo; Leah D. Fletcher; Deborah A. Dilts; John C. McMichael; Steven M. Baker
Archive | 2002
Leah D. Fletcher; John C. McMichael; David Russell; Robert John Zagursky